Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Talaris initiates FREEDOM-1 clinical trial for FCR001 in LDKT recipients Talaris Therapeutics has initiated the phase 3 FREEDOM-1 clinical trial to evaluate its investigational, allogeneic cell therapy FCR001… bypharmanewsdailyOctober 24, 2019